Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors.
Novo Nordisk’s Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin production, aiding blood clotting and stopping bleeding even in the absence/deficiency of other clotting factors. This enables Alhemo to promote clot formation even in the presence of inhibitors.
The drug is already approved in Australia and Switzerland for treating adolescents and adults (12 years and older) with hemophilia A or B with inhibitors. NVO also markets Alhemo in Japan to treat the same patient population (with and without inhibitors) and is used for routine prophylaxis to reduce or prevent bleeding episodes.
Year to date, shares of Novo Nordisk have gained 14.2% compared with the industry’s 20.6% growth.
Zacks Investment Research
Image Source: Zacks Investment Research
Per Novo Nordisk, the positive CHMP opinion recommending the approval of Alhemo in the EU is based on results from the phase III explorer7 study, which assessed the efficacy and safety of Alhemo for patients with hemophilia A or B with inhibitors. Subject to approval, Alhemo will come in a portable, pre-mixed, prefilled pen, allowing for quick and convenient subcutaneous administration and reducing the need for regular intravenous infusions, which will greatly reduce the treatment burden for patients and improve quality of life. Currently, patients living with haemophilia B with inhibitors have very limited treatment options.
Hemophilia is a rare bleeding disorder that hinders the body’s ability to form blood clots. It is commonly treated with replacement therapy, which involves intravenous infusions of the missing clotting factor. However, some patients develop inhibitors, an immune response that renders replacement therapy ineffective and limits treatment options, representing a high unmet medical need. NVO believes that around 30% of patients with severe hemophilia A and 5-10% of those with severe hemophilia B develop these inhibitors.
Novo Nordisk expects a final decision from the European Commission within the next two months.
Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
Story Continues
Novo Nordisk currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals ANIP, Alnylam Pharmaceuticals ALNY and Amicus Therapeutics FOLD. While ANIP currently sports a Zacks Rank #1 (Strong Buy), ALNY and FOLD carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share (EPS) have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 9.4%.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam’s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per shares estimates for 2025 have narrowed from 34 cents to 26 cents, during the same period. Year to date, shares of ALNY have risen 54.6%.
Alnylam’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
In the past 60 days, estimates for Amicus’ 2024 EPS have increased from 20 cents to 22 cents. EPS estimates for 2025 have increased from 48 cents to 53 cents, during the same period. Year to date, shares of FOLD have lost 16.1%.
Amicus’ earnings beat estimates in three of the four trailing four quarters, missing the mark once, with the average surprise being 23.96%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6716e6e2d00d4426a7cbf8379c24bb2b&url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fnvos-alhemo-gets-positive-chmp-155200060.html&c=6477845635233400397&mkt=de-de
Author :
Publish date : 2024-10-21 10:44:00
Copyright for syndicated content belongs to the linked Source.
